Pfizer Posts Quarterly Loss as COVID Product Demand Wanes, Pivots to Weight-Loss Drugs
Pfizer reported a Q4 loss driven by steep declines in its COVID-19 vaccine and antiviral sales, while highlighting promising early data for a newly acquired GLP-1 weight-loss therapy as it seeks to diversify its revenue stream.